| 000 | 01518 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250517000950.0 | ||
| 264 | 0 | _c20150914 | |
| 008 | 201509s 0 0 eng d | ||
| 022 | _a1545-326X | ||
| 024 | 7 |
_a10.1146/annurev-med-050913-022545 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLord, Christopher J | |
| 245 | 0 | 0 |
_aSynthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. _h[electronic resource] |
| 260 |
_bAnnual review of medicine _c2015 |
||
| 300 |
_a455-70 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 |
_aBenzamides _xtherapeutic use |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGenes, BRCA1 |
| 650 | 0 | 4 | _aGenes, BRCA2 |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aNeoplasms, Cystic, Mucinous, and Serous _xdrug therapy |
| 650 | 0 | 4 |
_aOvarian Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aPhthalazines _xtherapeutic use |
| 650 | 0 | 4 |
_aPiperazines _xtherapeutic use |
| 650 | 0 | 4 | _aPoly (ADP-Ribose) Polymerase-1 |
| 650 | 0 | 4 | _aPoly(ADP-ribose) Polymerase Inhibitors |
| 700 | 1 | _aTutt, Andrew N J | |
| 700 | 1 | _aAshworth, Alan | |
| 773 | 0 |
_tAnnual review of medicine _gvol. 66 _gp. 455-70 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1146/annurev-med-050913-022545 _zAvailable from publisher's website |
| 999 |
_c24301986 _d24301986 |
||